Citius pharmaceuticals, inc. reports fiscal third quarter 2022 financial results and provides business update

$48.0 million in cash and cash equivalents as of june 30, 2022 to support ongoing programs through august 2023 international sites for mino-lok® phase 3 trial engaged as recruitment accelerates i/ontak biologics license application (bla) on track for 2h 2022 submission cranford, n.j. , aug. 11, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the third fiscal quarter of 2022 ended june 30, 2022.
CTXR Ratings Summary
CTXR Quant Ranking